June 12, 2024Open Access

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy

Key Points

Key points are not available for this paper at this time.

Abstract

The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy, especially the risk of T-cell neoplasms related to viral vector integration, is an emerging concern.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Mark Hamilton

The University of Texas MD Anderson Cancer Center

Takeshi Sugio

California Institute for Regenerative Medicine

Troy Noordenbos

California Institute for Regenerative Medicine

Journals

New England Journal of Medicine

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Also consider